The global blood screening market is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases.
The key players in blood screening market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).
To know about the assumptions considered for the study download the pdf brochure
F. Hoffmann-La Roche Ltd. (Switzerland) maintained its dominant position in the blood screening market in 2022. The company's strong distribution networks in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa have contributed to its maintained leadership in the market. Roche continues to be at the top from a robust direct and indirect distribution network worldwide, which helps mitigate the impact of demand fluctuations across different regions. To further enhance its market dominance, the company employs inorganic growth strategies, such as partnerships and acquisitions. The company announced the acquisition of TIB Molbiol (Germany) in September 2021 in order to increase the breadth of infectious illness assays in its PC test platform. F. Hoffmann-La Roche Ltd. also devotes a sizeable portion of its earnings to research and development. This helps the business to create and introduce new items to the marketplace. The business introduced its Cobas 6800/8800 systems in March 2021. Roche is able to increase its market share and solidify its position in the blood screening industry thanks to these strategic actions.
Grifols held the second-largest market share for blood screening in 2022. Through its robust distribution networks in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa, the company has maintained a dominant position in the market. The corporation uses inorganic growth tactics to strengthen its position as the market leader. For instance, the corporation bought the Biotest (Germany) in September 2021. With this acquisition, Grifols improved its global reputation as a pioneer in the development of procedural plasma therapies. Such progress and advances will help Grifols to add unique technologies and products to their portfolio further strengthening their presence in the blood screening market.
Abbott Laboratories, Inc.'s (US) dominant position in this market can be ascribed to its robust global sales and distribution network, which allows it to successfully advertise its products across numerous nations. To acquire an edge in the market, it concentrates on enhancing its R&D capabilities. Due to this, Abbott was able to introduce cutting-edge products in the blood screening industry, such as the Alinity line of next-generation systems for blood and plasma screening, clinical chemistry, hematology, Po, and molecular diagnostics, which was unveiled in July 2019.
Related Reports:
Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE